Safety of cataract surgery in patients treated with the new oral anticoagulants (NOACs).

Abstract

To evaluate the safety of phacoemulsification of cataract in patients taking new oral anticoagulants (NOACs). In a prospective case series, consecutive patients on NOACs (dabigatran, rivaroxaban, or apixaban) who were referred for uncomplicated cataract surgery to the eye institute underwent a thorough ophthalmological and hematological evaluation. Rivaroxaban and apixaban anti-factor Xa tests, and diluted thrombin time for dabigatran, were used for monitoring anticoagulation levels in blood. Blood was drawn for these tests just prior to surgery and at a peak level of the drug at about 4h post-surgery (2h after the drug was given). All surgeries were videotaped and patients were examined at 1 and 7days after the operation. The main outcome measures included assessment of intra-operative, postoperative ocular bleeding, and other related complications. Thirty-five eyes of 25 unrelated patients ranging in age from 63 to 92years (mean 77.6years) underwent phacoemulsification. Intra-operative bleeding was observed in 5 eyes from the conjunctiva or limbus at the main incision site. No intraocular bleeding occurred. No hemorrhagic complications were observed during the 1-week follow-up. According to anti-factor Xa levels prior to surgery and following surgery, 85% of the patients were on therapeutic levels of NOACs. Clear corneal incision phacoemulsification performed under topical anesthesia can be safely performed in simple cases of cataract without discontinuing NOAC treatment.